Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Colin D. Porter is active.

Publication


Featured researches published by Colin D. Porter.


Journal of Immunological Methods | 1992

Superoxide production by normal and chronic granulomatous disease (CGD) patient-derived EBV-transformed B cell lines measured by chemiluminescence-based assays

Colin D. Porter; M. H. Parkar; M. K. L. Collins; Roland J. Levinsky; Christine Kinnon

We have compared assays for products of the neutrophil respiratory burst in normal EBV-transformed B cell lines stimulated with agonists of protein kinase C. Those measuring O2- directly or its immediate product, H2O2, were successful. Of these, the most sensitive were the lucigenin- and luminol-based chemiluminescence assays for O2- and H2O2 respectively. Cell lines from CGD patients, with X-linked or autosomal recessive genetic defects in the neutrophil NADPH oxidase, did not respond in these assays, indicative of their inability to produce O2-. The defects in the lines studied encompass both proteins forming the cytochrome b-245 membrane component, and the 47 kDa cytosolic component of the NADPH oxidase. The possession of the disease associated phenotype by these cell lines provides evidence that in the normal situation both neutrophils and B cells produce O2- via the same system.


Human Gene Therapy | 1999

In Vivo Transfer of Bacterial Marker Genes Results in Differing Levels of Gene Expression and Tumor Progression in Immunocompetent and Immunodeficient Mice

Katalin V. Lukacs; Colin D. Porter; Olivier E. Pardo; Ruth E. Oakley; Rachel Steel; Diane Judd; James E. Browning; Duncan M. Geddes; Eric W. F. W. Alton

To optimize gene delivery for the treatment of malignant mesothelioma, expression of the beta-galactosidase marker gene was examined in a murine model of intraperitoneal malignant mesothelioma. The beta-galactosidase gene was delivered to the peritoneal cavity of tumor-bearing mice by various plasmid-liposome complexes or by replication-incompetent retrovirus, used alone or complexed to liposomes. In tumor samples from immunodeficient nude mice, moderate levels of gene expression were achieved by liposome-complexed plasmids. Retroviral gene delivery was more effective, and was increased nearly 10-fold by complexing the retrovirus to liposomes. In contrast, in tumor samples from immunocompetent CBA mice treated with the same vectors, no marker gene expression was detected. In immunodeficient mice, tumor growth was not affected by beta-galactosidase gene transfer. However, immunocompetent mice showed a significant decrease in tumor size and increase in survival time after beta-galactosidase delivery. Induction of cytotoxic T cells capable of lysing beta-Gal-transfected tumor cells suggests that tumor cells transduced with the bacterial beta-galactosidase gene may be eliminated in immunocompetent hosts. Our findings also indicate that plasmid-liposome complexes, which achieve a low level of gene expression, and retrovirus-liposome complexes, which result in nearly 100 times higher levels of gene expression in tumor cells in vivo, are similarly effective in inducing an antitumor immune response.


Human Gene Therapy | 1996

Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors

Colin D. Porter; Mary Collins; Chetankumar S. Tailor; Mohamed H. Parkar; François-Loïc Cosset; Robin A. Weiss; Yasuhiro Takeuchi


Journal of Virology | 1998

Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo.

Colin D. Porter; Katalin V. Lukacs; Gary Box; Yasuhiro Takeuchi; Mary Collins


Blood | 1994

p22-phox-deficient chronic granulomatous disease: reconstitution by retrovirus-mediated expression and identification of a biosynthetic intermediate of gp91-phox

Colin D. Porter; M. H. Parkar; A. J. Verhoeven; Roland J. Levinsky; M. K. L. Collins; Christine Kinnon


Journal of Virology | 1999

Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences.

Ute Jäger; Yuan Zhao; Colin D. Porter


Blood | 1993

X-Linked Chronic Granulomatous Disease: Correction of NADPH Oxidase Defect by Retrovirus-Mediated Expression of gp91-phox

Colin D. Porter; M. H. Parkar; Roland J. Levinsky; M. K. L. Collins; Christine Kinnon


Biochemical Journal | 1996

Detection of gp91-phox precursor protein in B-cell lines from patients with X-linked chronic granulomatous disease as an indicator for mutations impairing cytochrome b558 biosynthesis

Colin D. Porter; F Kuribayashi; M. H. Parkar; Dirk Roos; Christine Kinnon


Blood | 1996

Efficient retroviral transduction of human bone marrow progenitor and long-term culture-initiating cells : Partial reconstitution of cells from patients with X-linked chronic granulomatous disease by gp91-phox expression

Colin D. Porter; M. H. Parkar; M. K. L. Collins; Roland J. Levinsky; Christine Kinnon


Human Mutation | 1996

Identification of a donor splice site mutation leading to loss of p22-phox exon 5 in autosomal chronic granulomatous disease.

Colin D. Porter; Mohamed H. Parkar; Christine Kinnon

Collaboration


Dive into the Colin D. Porter's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mary Collins

Carnegie Institution for Science

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Diane Judd

Imperial College London

View shared research outputs
Top Co-Authors

Avatar

Gary Box

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge